AP NEWS

Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR — What Drives Growth in Today’s Competitive Landscape

November 15, 2018

NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Knight-Swift Transportation Holdings Inc. (NYSE:KNX), Benitec Biopharma Limited (NASDAQ:BNTC), Eastern Company (NASDAQ:EML), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), Qualstar Corporation (NASDAQ:QBAK), and Nomura Holdings Inc ADR (NYSE:NMR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

KNX DOWNLOAD: http://Fundamental-Markets.com/register/?so=KNX BNTC DOWNLOAD: http://Fundamental-Markets.com/register/?so=BNTC EML DOWNLOAD: http://Fundamental-Markets.com/register/?so=EML KNSA DOWNLOAD: http://Fundamental-Markets.com/register/?so=KNSA QBAK DOWNLOAD: http://Fundamental-Markets.com/register/?so=QBAK NMR DOWNLOAD: http://Fundamental-Markets.com/register/?so=NMR

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Knight-Swift Transportation Holdings Inc. (NYSE:KNX), Benitec Biopharma Limited (NASDAQ:BNTC), Eastern Company (NASDAQ:EML), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), Qualstar Corporation (NASDAQ:QBAK), and Nomura Holdings Inc ADR (NYSE:NMR) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 13th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

KNIGHT-SWIFT TRANSPORTATION HOLDINGS INC. (KNX) REPORT OVERVIEW

Knight-Swift Transportation’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Knight-Swift Transportation reported revenue of $1,346.61MM vs $521.61MM (up 158.17%) and analysts estimated basic earnings per share $0.60 vs $0.04 (up 1,400.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Knight-Swift Transportation reported revenue of $2,425.45MM vs $1,118.03MM (up 116.94%) and analysts estimated basic earnings per share $4.38 vs $1.17 (up 274.36%). Analysts expect earnings to be released on January 29th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.52. The estimated EPS forecast for the next fiscal year is $2.71 and is expected to report on January 29th, 2019.

To read the full Knight-Swift Transportation Holdings Inc. (KNX) report, download it here: http://Fundamental-Markets.com/register/?so=KNX

-----------------------------------------

BENITEC BIOPHARMA LIMITED (BNTC) REPORT OVERVIEW

Benitec Biopharma’s Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Benitec Biopharma reported revenue of $0.69MM vs $4.39MM (down 84.21%) and analysts estimated basic earnings per share -$0.22 vs $0.08. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Benitec Biopharma reported revenue of $3.65MM vs $8.36MM (down 56.36%) and analysts estimated basic earnings per share -$0.86 vs -$0.49. Analysts expect earnings to be released on December 5th, 2018. The report will be for the fiscal period ending September 30th, 2018.

To read the full Benitec Biopharma Limited (BNTC) report, download it here: http://Fundamental-Markets.com/register/?so=BNTC

-----------------------------------------

EASTERN COMPANY (EML) REPORT OVERVIEW

Eastern’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Eastern reported revenue of $57.36MM vs $56.01MM (up 2.41%) and analysts estimated basic earnings per share $0.60 vs $0.36 (up 66.67%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Eastern reported revenue of $204.24MM vs $137.61MM (up 48.42%) and analysts estimated basic earnings per share $0.81 vs $1.25 (down 35.20%). Analysts expect earnings to be released on February 8th, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full Eastern Company (EML) report, download it here: http://Fundamental-Markets.com/register/?so=EML

-----------------------------------------

KINIKSA PHARMACEUTICALS, LTD. (KNSA) REPORT OVERVIEW

Kiniksa Pharmaceuticals’ Recent Financial Performance

Analysts expect earnings to be released on February 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The estimated EPS forecast for the next fiscal year is -$3.08 and is expected to report on February 7th, 2019.

To read the full Kiniksa Pharmaceuticals, Ltd. (KNSA) report, download it here: http://Fundamental-Markets.com/register/?so=KNSA

-----------------------------------------

QUALSTAR CORPORATION (QBAK) REPORT OVERVIEW

Qualstar’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Qualstar reported revenue of $3.15MM vs $2.76MM (up 14.48%) and analysts estimated basic earnings per share $0.20 vs -$0.07. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Qualstar reported revenue of $10.64MM vs $9.42MM (up 13.00%) and analysts estimated basic earnings per share $0.31 vs -$0.59. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full Qualstar Corporation (QBAK) report, download it here: http://Fundamental-Markets.com/register/?so=QBAK

-----------------------------------------

NOMURA HOLDINGS INC ADR (NMR) REPORT OVERVIEW

Nomura Holdings Inc ADR’s Recent Financial Performance

For the twelve months ended March 31st, 2018 vs March 31st, 2017, Nomura Holdings Inc ADR reported revenue of $17,749.42MM vs $15,954.30MM (up 11.25%) and analysts estimated basic earnings per share $0.57 vs $0.63 (down 9.20%). Analysts expect earnings to be released on February 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.22.

To read the full Nomura Holdings Inc ADR (NMR) report, download it here: http://Fundamental-Markets.com/register/?so=NMR

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

AP RADIO
Update hourly